Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis

References

• Strohlein MA, Heiss MM, Jauch KW. The current status of immunotherapy in peritoneal carcinomatosis. Expert Rev Anticancer Ther. 2016;16:1019–27. doi:10.1080/14737140.2016.1224666. PMID:27530056.
   PubMed Web of Science ®Google Scholar
• Lemoine L, Sugarbaker P, Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol. 2016;22:7692–707. doi:10.3748/wjg.v22.i34.7692. PMID:27678351.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Improving oncologic outcomes for colorectal cancer at high risk for local-regional recurrence with novel surgical techniques. Expert Rev Gastroenterol Hepatol. 2016;10:205–13. doi:10.1586/17474124.2016.1110019. PMID:26643935.
   PubMed Web of Science ®Google Scholar
• Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Annals Surg Oncol. 2009;16:2152–65. doi:10.1245/s10434-009-0487-4.
   PubMed Web of Science ®Google Scholar
• Morano WF, Aggarwal A, Love P, Richard SD, Esquivel J, Bowne WB. Intraperitoneal immunotherapy: historical perspectives and modern therapy. Cancer Gene Therapy. 2016;23:373–81. doi:10.1038/cgt.2016.49. PMID:27834358.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointestinal Oncol. 2010;2:68–75. doi:10.4251/wjgo.v2.i2.68.
   PubMed Web of Science ®Google Scholar
• Perrin P, Cassagnau E, Burg C, Patry Y, Vavasseur F, Harb J, Le Pendu J, Douillard JY, Galmiche JP, Bornet F, et al. An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology. 1994;107:1697–708. doi:10.1016/0016-5085(94)90810-9. PMID:7958681.
   PubMed Web of Science ®Google Scholar
• Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, Boutros C, Hanna N, Junghans RP. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Therapy. 2016;23:142–8. doi:10.1038/cgt.2016.14. PMID:27080226.
   PubMed Web of Science ®Google Scholar
• Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov. 2004;3:11–2. doi:10.1038/nrd1287. PMID:14756144.
   PubMed Web of Science ®Google Scholar
• Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, Berger W. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat. 2008;11:1–16. doi:10.1016/j.drup.2008.02.002. PMID:18394950.
   PubMed Web of Science ®Google Scholar
• Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci. 2002;59:1914–27. doi:10.1007/PL00012514. PMID:12530522.
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Seminars Oncol. 1998;25:4–12.
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1:227–35. PMID:12467217.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9. doi:10.1038/nm1622. PMID:17704786.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11:215–33. doi:10.1038/nrd3626. PMID:22301798.
   PubMed Web of Science ®Google Scholar
• Jungwirth U, Xanthos DN, Gojo J, Bytzek AK, Korner W, Heffeter P, Abramkin SA, Jakupec MA, Hartinger CG, Windberger U, et al. Anticancer activity of methyl-substituted oxaliplatin analogs. Mol Pharmacol. 2012;81:719–28. doi:10.1124/mol.111.077321. PMID:22331606.
   PubMed Web of Science ®Google Scholar
• Terenzi A, Pirker C, Keppler BK, Berger W. Anticancer metal drugs and immunogenic cell death. J Inorg Biochem. 2016;165:71–9. doi:10.1016/j.jinorgbio.2016.06.021. PMID:27350082.
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482–91. doi:10.1038/onc.2009.356. PMID:19881547.
   PubMed Web of Science ®Google Scholar
• Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102:115–23. doi:10.1038/sj.bjc.6605465. PMID:19997099.
   PubMed Web of Science ®Google Scholar
• Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene. 2011;30:1147–58. doi:10.1038/onc.2010.500. PMID:21151176.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121:3100–8. doi:10.1172/JCI43656. PMID:21765211.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Ann Rev Immunol. 2013;31:51–72. doi:10.1146/annurev-immunol-032712-100008.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967–70. doi:10.1126/science.1240527. PMID:24264989.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet M, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–6. doi:10.1126/science.1240537. PMID:24264990.
   PubMed Web of Science ®Google Scholar
• McCully ML, Madrenas J. Dendritic cells as arbiters of peritoneal immune responses. Perit Dial Int. 2006;26:8–25. PMID:16538869.
   PubMed Web of Science ®Google Scholar
• Melichar B, Freedman RS. Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer. 2002;12:3–17. doi:10.1046/j.1525-1438.2002.01093.x. PMID:11860531.
   PubMed Web of Science ®Google Scholar
• Witte A, Wanner G, Sulzner M, Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol. 1992;157:381–8. doi:10.1007/BF00248685. PMID:1534215.
   PubMed Web of Science ®Google Scholar
• Paukner S, Stiedl T, Kudela P, Bizik J, Al Laham F, Lubitz W. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opinion Drug Delivery. 2006;3:11–22. doi:10.1517/17425247.3.1.11.
   PubMedGoogle Scholar
• Kudela P, Koller VJ, Lubitz W. Bacterial ghosts (BGs)-Advanced antigen and drug delivery system. Vaccine. 2010;28:5760–7. doi:10.1016/j.vaccine.2010.06.087. PMID:20619379.
   PubMed Web of Science ®Google Scholar
• Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Controlled Release Official J Controlled Release Soc. 2004;94:63–74. doi:10.1016/j.jconrel.2003.09.010.
   PubMed Web of Science ®Google Scholar
• Stein E, Inic-Kanada A, Belij S, Montanaro J, Bintner N, Schlacher S, et al. In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases. Invest Ophthalmol Visual Sci. 2013;54:6326–33. doi:10.1167/iovs.13-12044.
   PubMed Web of Science ®Google Scholar
• Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013;39:806–18. doi:10.1016/j.immuni.2013.10.010. PMID:24238338.
   PubMed Web of Science ®Google Scholar
• Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006;34:455–65. doi:10.1080/01926230600867743. PMID:17067939.
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91. doi:10.1136/gutjnl-2015-310912. PMID:26818619.
   PubMed Web of Science ®Google Scholar
• Axelrod ML, Johnson DB, Balko JM. Emerging biomarkers for cancer immunotherapy in melanoma. Semin Cancer Biol. 2017. doi:10.1016/j.semcancer.2017.09.004. PMID:28917578.
   PubMed Web of Science ®Google Scholar
• Marrone KA, Brahmer JR. Using immune checkpoint inhibitors in lung cancer. Oncology (Williston Park). 2016;30:713–21. PMID:27528240.
   PubMed Web of Science ®Google Scholar
• Tsiatas M, Grivas P. Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med. 2016;4:270. doi:10.21037/atm.2016.06.29. PMID:27563657.
   PubMed Web of Science ®Google Scholar
• Boland PM, Ma WW. Immunotherapy for Colorectal Cancer. Cancers (Basel). 2017;9:E50. doi:10.3390/cancers9050050. PMID:28492495.
   PubMed Web of Science ®Google Scholar
• Coley WB. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus. Am J Med Sci. 1906;131:375–430.
   Google Scholar
• Oba MS, Teramukai S, Ohashi Y, Ogawa K, Maehara Y, Sakamoto J. The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials. Gastric Cancer. 2016;19:616–24. doi:10.1007/s10120-015-0489-9. PMID:25804300.
   PubMed Web of Science ®Google Scholar
• Singh R, Wallecha A. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic. Hum Vaccin. 2011;7:497–505. doi:10.4161/hv.7.5.15132. PMID:21422819.
   PubMed Web of Science ®Google Scholar
• Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20:142–52. doi:10.1200/JCO.2002.20.1.142. PMID:11773163.
   PubMed Web of Science ®Google Scholar
• Dzutsev A, Badger JH, Perez-Chanona E, Roy S, Salcedo R, Smith CK, Trinchieri G. Microbes and cancer. Annu Rev Immunol. 2017;35:199–228. doi:10.1146/annurev-immunol-051116-052133. PMID:28142322.
   PubMed Web of Science ®Google Scholar
• Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65–79. PMID:26000263.
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0 s that spur autophagy and immunity. Immunol Rev. 2012;249:158–75. doi:10.1111/j.1600-065X.2012.01146.x. PMID:22889221.
   PubMed Web of Science ®Google Scholar
• Muhammad A, Champeimont J, Mayr UB, Lubitz W, Kudela P. Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert Rev Vaccines. 2012;11:97–116. doi:10.1586/erv.11.149. PMID:22149712.
   PubMed Web of Science ®Google Scholar
• Krasko JA, Zilionyte K, Darinskas A, Strioga M, Rjabceva S, Zalutsky I, Derevyanko M, Kulchitsky V, Lubitz W, Kudela P, et al. Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. Oncol Rep. 2017;37:171–8. doi:10.3892/or.2016.5252. PMID:27878261.
   PubMed Web of Science ®Google Scholar
• Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014;20:2831–7. doi:10.1158/1078-0432.CCR-13-3141. PMID:24879823.
   PubMed Web of Science ®Google Scholar
• Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta. 2010;1805:53–71. PMID:19720113.
   PubMed Web of Science ®Google Scholar
• Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321–34. doi:10.1016/j.cell.2005.08.032. PMID:16239148.
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334:1573–7. doi:10.1126/science.1208347. PMID:22174255.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111. doi:10.1038/nri.2016.107. PMID:27748397.
   PubMed Web of Science ®Google Scholar
• Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annual Rev Immunol. 2010;28:367–88. doi:10.1146/annurev.immunol.021908.132603.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Q, Sun Q, Zhang C, Chen T, Cao X. TLR4 signaling in cancer cells promotes chemoattraction of immature dendritic cells via autocrine CCL20. Biochem Biophys Res Commun. 2008;366:852–6. doi:10.1016/j.bbrc.2007.12.030. PMID:18083111.
   PubMed Web of Science ®Google Scholar
• O'Leary DP, Bhatt L, Woolley JF, Gough DR, Wang JH, Cotter TG, Redmond HP. TLR-4 signalling accelerates colon cancer cell adhesion via NF-kappaB mediated transcriptional up-regulation of Nox-1. PLoS One. 2012;7:e44176. doi:10.1371/journal.pone.0044176. PMID:23071493.
   PubMed Web of Science ®Google Scholar
• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003;85:85–95. doi:10.1016/S0165-2478(02)00228-6. PMID:12527213.
   PubMed Web of Science ®Google Scholar
• Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tör M, Billiar T. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev. 2007;220:60–81. doi:10.1111/j.1600-065X.2007.00579.x. PMID:17979840.
   PubMed Web of Science ®Google Scholar
• Fang H, Ang B, Xu X, Huang X, Wu Y, Sun Y, Wang W, Li N, Cao X, Wan T. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol. 2014;11:150–9. doi:10.1038/cmi.2013.59. PMID:24362470.
   PubMed Web of Science ®Google Scholar
• Michalek J, Hezova R, Turanek-Knotigova P, Gabkova J, Strioga M, Lubitz W, Kudela P. Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells. Cancer Immunol Immunother. 2017;66:149–59. doi:10.1007/s00262-016-1932-4. PMID:27864613.
   PubMed Web of Science ®Google Scholar
• Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 2003;63:4112–8. PMID:12874015.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng Z, Zhang Q, Zhou X, Feng Y, Yan A. FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis. Onco Targets Ther. 2017;10:2621–33. doi:10.2147/OTT.S138011. PMID:28572734.
   PubMed Web of Science ®Google Scholar
• Schijns V, Tartour E, Michalek J, Stathopoulos A, Dobrovolskiene NT, Strioga MM. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Cytotherapy. 2014;16:427–39. doi:10.1016/j.jcyt.2013.09.008. PMID:24280238.
   PubMed Web of Science ®Google Scholar
• Liu Y, O'Leary CE, Wang LS, Bhatti TR, Dai N, Kapoor V, Liu P, Mei J, Guo L, Oliver P, et al. CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology. 2016;5:e1061175. doi:10.1080/2162402X.2015.1061175. PMID:26942073.
   PubMed Web of Science ®Google Scholar
• Hu X, Zhou Y, Dong K, Sun Z, Zhao D, Wang W, Yu G, Liu W, Xu G, Han Z, et al. Programming of the development of tumor-promoting neutrophils by mesenchymal stromal cells. Cell Physiol Biochem. 2014;33:1802–14. doi:10.1159/000362959. PMID:24923759.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70:325–30. doi:10.1016/j.humimm.2009.02.008. PMID:19236898.
   PubMed Web of Science ®Google Scholar
• Takeya M, Komohara Y. Role of tumor-associated macrophages in human malignancies: friend or foe? Pathol Int. 2016;66:491–505. doi:10.1111/pin.12440. PMID:27444136.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38:1074–84. doi:10.1002/hed.24406. PMID:26879675.
   PubMed Web of Science ®Google Scholar
• Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, Vermorken JB. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010;11:19. doi:10.1186/1471-2172-11-19. PMID:20385003.
   PubMed Web of Science ®Google Scholar
• Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117:451–60. doi:10.1038/bjc.2017.220. PMID:28704840.
   PubMed Web of Science ®Google Scholar
• Li L, Wang W, Pan H, Ma G, Shi X, Xie H, Liu X, Ding Q, Zhou W, Wang S. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J Transl Med. 2017;15:23. doi:10.1186/s12967-017-1124-9. PMID:28137271.
   PubMed Web of Science ®Google Scholar
• Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987;137:155–8. doi:10.1016/S0022-5347(17)43909-7. PMID:3491909.
   PubMed Web of Science ®Google Scholar
• Tel J, Hato SV, Torensma R, Buschow SI, Figdor CG, Lesterhuis WJ, de Vries IJ. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother. 2012;61:1101–11. doi:10.1007/s00262-011-1189-x. PMID:22193989.
   PubMed Web of Science ®Google Scholar
• Uehara K, Ichida T, Sugahara S, Ishikawa T, Yamagiwa S, Yoshida Y, Nomoto M, Katoh M, Satoh H, Watanabe H, et al. Systemic administration of liposome-encapsulated OK-432 prolongs the survival of rats with hepatocellular carcinoma through the induction of IFN-gamma-producing hepatic lymphocytes. J Gastroenterol Hepatol. 2002;17:81–90. doi:10.1046/j.1440-1746.2002.02675.x. PMID:11895558.
   PubMed Web of Science ®Google Scholar
• Berzins SP, Ritchie DS. Natural killer T cells: drivers or passengers in preventing human disease? Nat Rev Immunol. 2014;14:640–6. doi:10.1038/nri3725. PMID:25103356.
   PubMed Web of Science ®Google Scholar
• Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N, et al. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol. 2009;182:5140–51. doi:10.4049/jimmunol.0711086. PMID:19342695.
   PubMed Web of Science ®Google Scholar
• Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The Bacterial Ghost platform system: production and applications. Bioengineered Bugs. 2010;1:326–36. doi:10.4161/bbug.1.5.12540. PMID:21326832.
   PubMedGoogle Scholar
• Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–91. doi:10.1093/carcin/21.4.585. PMID:10753190.
   PubMed Web of Science ®Google Scholar
• Grusch M, Schelch K, Riedler R, Reichhart E, Differ C, Berger W, Inglés-Prieto Á, Janovjak H. Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. EMBO J. 2014;33:1713–26. doi:10.15252/embj.201387695. PMID:24986882.
   PubMed Web of Science ®Google Scholar
• Kuo C, Coquoz O, Troy TL, Xu H, Rice BW. Three-dimensional reconstruction of in vivo bioluminescent sources based on multispectral imaging. J Biomed Opt 2007; 12:024007. doi:10.1117/1.2717898. PMID:17477722.
   PubMed Web of Science ®Google Scholar
• Geyer A, Taschauer A, Alioglu F, Anton M, Maier J, Drothler E, Simlinger M, Yavuz S, Sami H, Ogris M. Multimodal Fluorescence and Bioluminescence Imaging Reveals Transfection Potential of Intratracheally Administered Polyplexes for Breast Cancer Lung Metastases. Hum Gene Ther. 2017;28(12):1202–1213. doi:10.1089/hum.2017.137. PMID:28874076.
   PubMed Web of Science ®Google Scholar
• Boll H, Figueiredo G, Fiebig T, Nittka S, Doyon F, Kerl HU, Nölte I, Förster A, Kramer M, Brockmann MA. Comparison of Fenestra LC, ExiTron nano 6000, and ExiTron nano 12000 for micro-CT imaging of liver and spleen in mice. Academic Radiol. 2013;20:1137–43. doi:10.1016/j.acra.2013.06.002.
   PubMed Web of Science ®Google Scholar
• Rampurwala M, Ravoori MK, Wei W, Johnson VE, Vikram R, Kundra V. Visualization and quantification of intraperitoneal tumors by in vivo computed tomography using negative contrast enhancement strategy in a mouse model of ovarian cancer. Translational Oncol. 2009;2:96–106. doi:10.1593/tlo.08199.
   PubMed Web of Science ®Google Scholar
• Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest. 2012;122:575–85. doi:10.1172/JCI61034. PMID:22251703.
   PubMed Web of Science ®Google Scholar